Aug 14, 2023 4:30 pm EDT SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 20, 2023 9:58 am EDT SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Jun 21, 2023 7:00 am EDT SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
May 12, 2023 8:00 am EDT SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
May 11, 2023 7:00 am EDT SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
Apr 13, 2023 8:30 am EDT SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
Mar 31, 2023 8:30 am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 30, 2023 7:05 am EDT GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Dec 1, 2022 8:00 am EST SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
